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Abstract
Protein-protein interaction networks associated with diseases have
gained prominence as an area of research. We investigate algebraic and
topological indices for protein-protein interaction networks of 11 human
cancers derived from the Kyoto Encyclopedia of Genes and Genomes
(KEGG) database. We find a strong correlation between relative au-
tomorphism group sizes and topological network complexities on the one
hand and five year survival probabilities on the other hand. Moreover,
we identify several protein families (e.g. PIK, ITG, AKT families) that
are repeated motifs in many of the cancer pathways. Interestingly, these
sources of symmetry are often central rather than peripheral. Our re-
sults can aide in identification of promising targets for anti-cancer drugs.
Beyond that, we provide a unifying framework to study protein-protein
interaction networks of families of related diseases (e.g. neurodegenerative
diseases, viral diseases, substance abuse disorders).
Introduction
Biological networks have been an active area of research for some years, see
e.g. [12, 16, 17] and the references therein. In earlier work [6] we reported
that molecular signaling network complexity is correlated with cancer patient
survival. In that work we reported a statistical mechanics measure of network
complexity. Here we focus on the relative sizes of automorphism groups and the
dimensions of the cycle spaces (cyclomatic numbers).
Complex real-world networks contain feedback loops to enable the network
“communication” to continue in the face of node failure [2]. In the case of
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protein-protein interaction (PPI) networks this means that inhibition of a spe-
cific node may or may not have any effect. It is well known that targeting hub
nodes in networks often causes the network to break up into multiple compo-
nents and this could be lethal, because many protein hubs in PPIs for cancer
are also important proteins in metabolic networks. As we argued in [6], tar-
geting nodes with high-betweenness has higher potential for improved cancer
treatment. Selective targeting of nodes in a PPI for cancer treatment is fraught
with difficulties.
In this letter we apply two more algebraic and topological indices to study
cancer PPI networks and show correlation with 5 year patient survival. We
identify several repeated motifs of proteins that are “interchangeable” in a sense
to be specified below. In the long run we anticipate that the methods described
here will aid identification of potential drug targets.
Results and Discussion
A network is an undirected graph G = (V,E) with vertex set V and edge set
E. The vertices are proteins and two vertices are connected by an edge if there
is a known interaction of the two partners, either by direct binding or by enzy-
matic catalysis. Beyond cancer pathways, the Kyoto Encyclopedia of Genes and
Genomes (KEGG) database also contains pathways related to immune diseases
(e.g. asthma), neurodegenerative diseases (Alzheimer’s disease, Parkinson’s dis-
ease), substance dependence, cardiovascular diseases, viral diseases and many
others [13]. The KEGG networks are assembled from the literature by searches
for experimental confirmation of the relevant interactions. Each interaction
is always confirmed by two or more different experimental techniques such as
pull-down mass spectrometry, yeast two-hybrid and various biochemical tests.
Naturally, networks constructed from experimental results are likely to contain
errors, which are however impossible to quantify.
An automorphism is a permutation φ : V → V that preserves the adjacency
relation, that is,
(u, v) ∈ E ⇔ (φ(u), φ(v)) ∈ E.
With the operation of composition, the automorphisms form a group Aut(G).
The relation on the set of vertices
u ∼ v ⇔ there exists a φ ∈ Aut(G) such that v = φ(u)
is an equivalence relation and its equivalence classes are called the (group) orbits.
MacArthur et al. [18] list 20 examples of real world networks and their rich
symmetry groups. This is in contrast to large random graphs, such as graphs
from the Erdo˝s-Re´nyi model G(n, p). Here n is the number of vertices. Edges are
independently present with probability 0 < p < 1. Such graphs have only the
trivial automorphism, with probability approaching one, in the limit n→∞ [5,
Chapter IX]. The difference is not surprising if one realizes that real networks
display a modular structure, with vertices organized in communities tightly
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connected internally and loosely connected to each other [10]. This results in
the presence of symmetric subgraphs such as trees and complete cliques.
Figure 1 shows as an example the protein-protein interaction network of
pancreatic cancer as retrieved from the KEGG database. We find that the
automorphism group of this network is the direct product of symmetric groups
Aut(G) = S92 × S63 × S25 × S8,
see Table 1 for a complete list of automorphism groups. Remarkably, symmetries
do not only arise due to tree subgraphs at the “ends” of the network, but also
due to central nodes of high degree (highlighted in yellow in Figure 1). Thus any
flow of information that passes through one node in such an orbit equivalence
class may pass through any other node in the same equivalence class. The
presence of such modular patterns indicates a high level of redundancy which
confers robustness to the associated biological system (tumor cells). We suggest
that to interrupt the flow through such a network most efficiently, the nodes
adjacent to large central orbits are the best to be targeted for example by
pharmacological agents that inhibit a specific protein-protein interaction pair.
Similar suggestions have been made in [7, 8, 22]. The use of automorphism
groups has, to the best of our knowledge, not yet been proposed.
Automorphism groups are often used to measure the complexity of a network
[23]. In order to make automorphism group sizes of graphs with n = |V | vertices
comparable, we follow the suggestion in [23] and compute the ratio
βG =
( |Aut(G)|
n!
) 1
n
.
This relates the size of Aut(G) to the size of the automorphism group Sn of the
complete graph on n vertices.
A second graph invariant is of a more topological nature. A cycle is a
sequence of adjacent vertices that starts and ends at the same vertex. The set
of all cycles C(G) can be made a vector space over the field Z2 by taking the
symmetric difference
C1∆C2 = (C1 ∪ C2) \ (C1 ∩ C2)
as addition, the identity as negation, and the empty cycle as zero. The dimension
of this vector space is called the cyclomatic number µG, or the circuit rank.
Loosely speaking, it is a count of the “independent” loops, see Figure 2. It
is shown in [4, 15] that for a graph with n vertices, m edges and c connected
components, µG is given by
µG = m− n+ c.
We plot these two indices against the five year survival probability p, ob-
tained from the Surveillance, Epidemiology and End Results (SEER) database
[20] for 11 types of cancer in Figure 3. Interaction networks with larger values of
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βG or equivalently greater symmetry are associated with better chances of sur-
vival. A large value of µG indicates high topological complexity and correlates
with decreased chance of survival. We find that both coefficients of determi-
nation are R2 = 0.52 with corresponding p-value p = 0.011 (the equality is
coincidental). There are widespread differences in detection stage, metastasis
status, treatment and general health of the patient which are unfortunately not
accessible from the SEER database. Nevertheless, given this large amount of
natural uncertainty in the data, this indicates a strong correlation of averages. It
would be invaluable for future research to classify database entries according to
some of the parameters mentioned above. Since both the automorphism group
size βG and the cyclomatic number µG are correlated to the five year survival
probability p, it is to be expected that these two quantities are correlated to
each other, for the the protein-protein interaction networks of cancers that are
the object of our study, see Figure 4, left panel. However, it is easy to construct
examples of graphs that show no correlation between βG and µG, see Figure 4,
right panel.
Further study of the automorphism groups reveals repeated motifs in sev-
eral interaction networks. The eight proteins from the PIK3C{A,B,D,G} and
PIK3R{1,2,3,5} family form a single orbit equivalence class in seven of the net-
works (AML, CML, colorectal, endometrial, pancreatic, renal and SCL cancers)
and are split in two orbit equivalence class in two more networks (glioma and
NSCL). The three proteins AKT{1,2,3} are orbit equivalent in eight networks
(CML, colorectal, endometrial, glioma, NSCL, pancreatic, renal and SCL can-
cers), that is, whenever they appear in the network to begin with. These players
have been known for a long time to be of crucial importance to the initiation
and progression of cancer, mainly due to the various biological and biochemical
assays performed on cancer cells. However, our conclusions stem directly from
a group-theoretic analysis of the PPI networks and they are network specific.
Since its initial discovery as a proto-oncogene, the serine/threonine kinase AKT
has become a major focus of attention because of its critical regulatory role in
diverse cellular processes, including cancer progression and insulin metabolism.
The AKT cascade is activated by receptor tyrosine kinases, integrins, B and
T cell receptors, cytokine receptors, G-protein-coupled receptors and other
stimuli that induce the production of phosphatidylinositol (3,4,5)-triphosphates
(PtdIns(3,4,5)P3) by phosphoinositide 3-kinase (PI3K). These lipids serve as
plasma membrane docking sites for proteins that harbor pleckstrin-homology
(PH) domains, including AKT and its upstream activator PDK1. The tumor
suppressor PTEN is recognized as a major inhibitor of AKT and is frequently
lost in human tumors. There are three highly related isoforms of AKT (AKT1,
AKT2, and AKT3), which represent the major signaling arm of PI3K. For exam-
ple, germline mutations of AKT have been identified in pathological conditions
of cancer and insulin metabolism. AKT regulates cell growth through its effects
on the TSC1/TSC2 complex and mTOR pathways, as well as cell cycle and cell
proliferation through its direct action on the CDK inhibitors p21 and p27, and
its indirect effect on the levels of cyclin D1 and p53. AKT is a major mediator
of cell survival through direct inhibition of pro-apoptotic signals such as the
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pro-apoptotic regulator BAD and the FOXO and Myc family of transcription
factors. AKT has been demonstrated to interact with Smad molecules to reg-
ulate TGF-β signaling. These findings make AKT an important therapeutic
target for the treatment of cancer.
Interestingly, the network of small cell lung cancer contains an enormous
orbit of 18 equivalent nodes of degree six. This orbit consists of laminines,
collagens and a fibronectin that are major proteins in the basal lamina. All
nodes are connected to six members of the integrin family of transmembrane
receptors.
Conclusion
We have shown that the relative size of the automorphism groups and the cy-
clomatic numbers for cancer pathway networks from the KEGG database are
both correlated with five-year survival of cancer patients. Determination of the
specific reasons for these great discrepancies in survival rates remains a topic
for future research. Interestingly, cancers with more symmetric interaction net-
works are associated with better survival rates. This may be due to a greater
robustness to failure, which, somewhat counterintuitive, is a positive feature in
this context.
We suggest that selective removal of nodes from the network (clinically equiv-
alent to protein inhibition) and reinterpolation on the linear curves helps to
identify potential drug targets. This indicates that complexity of a biochemi-
cal network involved in a deregulated cell cycle as exemplified by cancer cells
is of crucial importance to its robustness. This is manifested by various re-
dundancies in the PPI network that make the search for a therapeutic “silver
bullet” an impossible task. We suggest that selective removal of nodes from
the network (clinically equivalent to protein inhibition) and reinterpolation on
the linear curves helps to identify potential drug targets. We have shown that
PI3K and AKT families of proteins appear to be the most suitable targets for
pharmacological inhibition in the most number of cancer types studied. It is
encouraging that there are several AKT pathway inhibitors in clinical develop-
ment, e.g. perifosine (KRX-0401, Aeterna Zentaris/Keryx), MK-2206 (Merck),
and GSK-2141795 (Glaxo-SmithKline) [3]. Similarly, Bayer, GlaxoSmithKline
(GSK), Novartis, Merck & Co., Roche and Sanofi are just a few of the companies
that have placed great importance on the development of a spectrum of agents
targeting the PI3K pathway. Drug candidates including pan-PI3K inhibitors,
PI3K isoform-specific inhibitors, AKT inhibitors and mTOR inhibitors are cur-
rently tested alone and in combinations in an array of cancer indications [11].
While the motivation for this focus has been stated as: The pathway is almost
invariably on in cancer, our methodology identifies this pathway as the most
crucial using mathematical analysis of the network. Moreover, we are able to
identify those types of cancer where the pathway should be the main target and
those types where targeting it may not produce the expected clinical outcomes.
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Methods
The cancer pathways were obtained from the Kyoto Encyclopedia of Genes
and Genomes (KEGG) [13] with the help of the open source software packages
KEGGgraph [24] and cytoscape [21]. The automorphism groups of the networks
were found with saucy [14] and gap [9] (see Tables 2-12 for the complete group
lists). Bases of the cycle spaces were found using python networkX.
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Figure 1: The protein-protein interaction network of pancreatic cancer. The net-
work was retrieved from the KEGG database [13] and its automorphism group
determined with saucy [14], namely Aut(G) = S92 × S63 × S25 × S8. Highlighted
in yellow are three central orbits of nodes of degrees 3, 4 and 8, respectively.
Two of these are the PI3K and the AKT families, respectively.
C1 C2
C3
Figure 2: The cycle space of a simple graph with four vertices. The graph G
is shown in black and three cycles C1, C2 and C3 are marked in red, blue and
green, respectively. Any of the sets {C1, C2}, {C1, C3} and {C2, C3} is a basis
of the cycle space C(G) = {C1, C2, C3}.
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Figure 3: Automorphism group sizes and cyclomatic numbers. A plot of relative
automorphism group size βG (left) and cyclomatic number µG (right) against
five year survival probability p for 11 types of cancer. In both cases we have
the coefficients of determination R2 = 0.52 and p = 0.011. The cancer types
are AML: acute myelogeneous leukemia, Bld: bladder cancer, CML: chronic
myelogeneous leukemia, Col: colorectal cancer, End: endometrial cancer, Gli:
Glioma, NSCL: non-small cell lung cancer, Pc: pancreatic cancer, Ren: renal
cancer, SCL: small cell lung cancer, Thyr: thyroid cancer. The width of the
horizontal error bars is 0.1, the width of the vertical error bars is 0.02 in the left
panel and 20 in the right panel. These errors are estimated as the actual error
is unknown.
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Figure 4: Mutual relation between βG and µG. (Left) A plot of cyclomatic
number µG against relative automorphism group size βG for the 11 protein-
protein interaction networks of cancers. (Right) In general, these quantities are
not related. Shown are a highly symmetric graph with trivial cycle space and
an asymmetric graph with large cycle space.
Tables
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Cancer n Aut(G) |Aut(G)| c βG µG
AML 62 S72 × S43 × S4 × S27 1.011 · 1014 1 7.03 · 10−2 108
Bld 29 S52 × S33 × S4 1.658 · 105 3 1.29 · 10−1 20
CML 73 S82 × S73 × S4 × S25 × S8 9.98 · 1017 3 6.3 · 10−2 115
Col 49 S52 × S43 × S24 × S8 9.63 · 1011 3 9.2 · 10−2 58
End 44 S52 × S43 × S4 × S5 × S8 4.82 · 1012 2 1.1 · 10−1 45
Gli 64 S82 × S63 × S44 × S6 2.85 · 1015 2 7.0 · 10−2 128
NSCL 48 S72 × S53 × S34 1.37 · 1010 1 8.6 · 10−2 75
Pc 69 S92 × S63 × S25 × S8 1.39 · 1016 4 6.4 · 10−2 72
Ren 60 S82 × S23 × S6 × S8 × S18 1.7 · 1027 3 1.2 · 10−1 52
SCL 77 S42 × S43 × S4 × S6 × S8 × S12 × S18 4.4 · 1037 2 1.0 · 10−1 150
Thyr 28 S42 × S23 × S4 × S7 7.0 · 107 3 1.7 · 10−1 24
Table 1: Automorphism groups of all cancers. Column n contains the number of
vertices, column c contains the number of connected components of the protein-
protein interaction network. The abbreviations are the same as in Figure 3.
Nodes Degree
PIK3R5 PIK3CA PIK3CB PIK3CD PIK3R1 PIK3R2 PIK3R3 9
CCND1 MYC PPARD LEF1 TCF7 TCF7L2 TCF7L1 1
KRAS NRAS HRAS 12
RPS6KB1 RPS6KB2 EIF4EBP1 5
STAT3 STAT5A STAT5B 5
RARA PML LOC652346 LOC652671 3
ARAF RAF1 BRAF 1
KIT LOC652799 12
IKBKB IKBKG 5
MAP2K1 MAP2K2 5
SOS1 SOS2 4
PIM1 PIM2 3
NFKB1 RELA 3
MAPK1 MAPK3 2
Table 2: Orbit equivalence classes for the AML group.
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Nodes Degree
DAPK1 DAPK3 DAPK2 RPS6KA5 2
KRAS NRAS HRAS 5
ARAF RAF1 BRAF 5
E2F1 E2F2 E2F3 1
MAPK1 MAPK3 6
MAP2K1 MAP2K2 5
RASSF1 FGFR3 3
CCND1 CDK4 3
EGFR ERBB2 1
Table 3: Orbit equivalence classes for the bladder cancer group.
Nodes Degree
PIK3R5 PIK3CA PIK3CB PIK3CD PIK3CG PIK3R1 PIK3R2 PIK3R3 9
CRK CRKL CBLC CBL CBLB 9
SHC2 SHC4 SHC3 SHC1 MYC 2
HDAC1 HDAC2 CTBP1 CTBP2 2
AKT1 AKT2 AKT3 14
ARAF RAF1 BRAF 5
KRAS NRAS HRAS 5
CHUK IKBKB IKBKG 4
CDK4 CDK6 CCND1 3
E2F1 E2F2 E2F3 1
ABL1 BCR 13
MAP2K1 MAP2K2 5
SOS1 SOS2 4
MECOM RUNX1 4
STAT5A STAT5B 3
MAPK1 MAPK3 2
TGFRB1 TGFRB2 2
NFKB1 RELA 1
Table 4: Orbit equivalence classes for the CML group.
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Nodes Degree
PIK3R5 PIK3CA PIK3CB PIK3CD PIK3CG PIK3R1 PIK3R2 PIK3R3 4
RHOA RAC1 RAC2 RAC3 4
LEF1 TCF7 TCF7L1 TCF7L2 4
AKT1 AKT2 AKT3 8
MAPK8 MAPK9 MAPK10 4
ARAF RAF1 BRAF 2
SMAD4 TGFBR1 TGFBR2 2
MAPK1 MAPK3 4
JUN FOS 3
DCC CASP3 3
SMAD2 SMAD3 3
Table 5: Orbit equivalence classes for the colorectal cancer group.
Nodes Degree
PIK3R5 PIK3CA PIK3CB PIK3CD PIK3CG PIK3R1 PIK3R2 PIK3R3 3
APC2 APC AXIN1 AXIN2 GSK3B 1
LEF1 TCF7 TCF7L1 TCF7L2 3
AKT1 AKT2 AKT3 5
KRAS NRAS HRAS 5
ARAF RAF1 BRAF 5
BAD CASP9 FOXO3 3
PDPK1 ILK 10
MAP2K1 MAP2K2 5
MAPK1 MAPK3 3
SOS1 SOS2 4
MYC CCND1 4
DCC CASP3 3
Table 6: Orbit equivalence classes for the endometrial cancer group.
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Nodes Degree
CALML6 CALML5 CALM1 CALM2 CALM3 CALML3 3
PIK3CA PIK3CB PIK3CD PIK3CG 9
CAMK2A CAMK2B CAMK2D CAMK2G 8
PIK3R5 PIK3R1 PIK3R2 PIK3R3 7
SHC1 SHC2 SHC3 SHC4 5
KRAS NRAS HRAS 20
ARAF RAF1 BRAF 5
PRKCA PRKCB PRKCG 3
CCND1 CDK4 CDK6 3
AKT1 AKT2 AKT3 1
E2F1 E2F2 E2F3 1
PDGFRA PDGFRB 16
MAP2K1 MAP2K2 9
PLCG1 PLCG2 4
SOS1 SOS2 4
MDM2 ↔ TP53 (2) CDKN2A ↔ CDKN1A (4) -
MAPK1 MAPK3 2
PDGFA PDGFB 2
EGF TGFA 1
Table 7: Orbit equivalence classes for the glioma group. The nodes MDM2
and TP53 can only be permuted simultaneously with the nodes CDKN1A and
CDKN2A.
Nodes Degree
PIK3CA PIK3CB PIK3CD PIK3CG 7
PIK3R5 PIK3R1 PIK3R2 PIK3R3 5
PLCG1 PLCG2 TGFA EGF 2
AKT1 AKT2 AKT3 12
ARAF RAF1 BRAF 8
PRKCA PRKCB PRKCG 3
CCND1 CDK4 CDK6 3
BAD CASP9 FOXO3 3
E2F1 E2F2 E2F3 1
EGFR ERBB2 9
NRAS HRAS 5
MAP2K1 MAP2K2 4
SOS1 SOS2 4
MAPK1 MAPK3 3
STK4 RASSF5 2
CDK4 CDK6 2
Table 8: Orbit equivalence classes for the NSCL group.
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Nodes Degree
PIK3R5 PIK3CA PIK3CB PIK3CD PIK3CG PIK3R1 PIK3R2 PIK3R3 3
FIGF PGF VEGFA VEGFB VEGFC 4
MAPK1 MAPK3 MAPK8 MAPK9 MAPK10 1
AKT1 AKT2 AKT3 8
CHUK IKBKB IKBKG 5
RAC1 RAC2 RAC3 4
ARAF RAF1 BRAF 2
TGFB1 TGFB2 TGFB3 2
E2F1 E2F2 E2F3 1
RELA NKFB1 14
STAT1 STAT3 6
TGFBR1 TGFBR2 6
BAD BCL2L1 4
RALA RALB 3
CDK4 CDK6 3
SMAD2 SMAD3 3
BRCA2 RAD51 1
TGFA EGF 1
Table 9: Orbit equivalence classes for the pancreatic cancer group.
Nodes Degree
ARNT ARNT2 CREBBP EP300 EGLN2 EGLN3 EGLN1 SLC2A1
2FIGF PGF VEGFA VEGFB VEGFC TGFB1 TGFB2 TGFB3
PDGFB TGFA
PIK3R5 PIK3CA PIK3CB PIK3CD PIK3CG PIK3R1 PIK3R2 PIK3R3 4
PAK1 PAK2 PAK3 PAK4 PAK6 PAK7 2
AKT1 AKT2 AKT3 8
ARAF RAF1 BRAF 2
EPAS1 HIF1A 18
RAC1 CDC42 6
MAPK1 MAPK3 5
MAP2K1 MAP2K2 5
ETS1 JUN 2
CRK CRKL 2
SOS1 SOS2 1
RAP1A RAP1B 1
Table 10: Orbit equivalence classes for the renal group.
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Nodes Degree
LAMA1 LAMA2 LAMA3 LAMA4 LAMA5 LAMB1 LAMB2 LAMB3
6LAMB4 LAMC1 LAMC2 LAMC3 COL4A1 COL4A2 COL4A4 COL4A5
COL4A6 FN1
TRAF1 TRAF2 TRAF3 TRAF4 TRAF5 TRAF6
2
PTGS2 NOS2 BIRC2 BIRC3 XIAP BCL2L1
PIK3R5 PIK3CA PIK3CB PIK3CD PIK3CG PIK3R1 PIK3R2 PIK3R3 4
PIAS1 PIAS2 PIAS3 PIAS4 3
AKT1 AKT2 AKT3 11
CHUK IKBKB IKBKG 4
CCNE1 CCNE2 CDK2 2
E2F1 E2F2 E2F3 1
RELA NKFB1 13
MAX MYC 8
CDK4 CDK6 4
APAF1 CYCS 1
Table 11: Orbit equivalence classes for the SCL group.
Nodes Degree
RET CCDC6 NCOA4 TFG NTRK1 TPM3 TPR 3
LEF1 TCF7 TCF7L1 TCF7L2 3
KRAS NRAS HRAS 8
RXRA RXRB RXRG 2
MYC CCND1 4
MAP2K1 MAP2K2 3
PPARG PAX8 3
MAPK1 MAPK3 2
Table 12: Orbit equivalence classes for the thyroid cancer group.
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